卡培他滨维持治疗在晚期三阴性乳腺癌中的生存获益分析

打开文本图片集

DOI：10.16424/j.cnki.cn32-1807/r.2025.04.004

[关键词]晚期乳腺癌；卡培他滨；肿瘤标志物；炎症反应；免疫功能 [中图分类号]R737.9 [文献标志码]A [文章编号] 1674-7887（2025）04-0327-05

Survival benefitanalysisof capecitabinemaintenance therapyin advanced triple-negative breast cancer*

XUTonglin**，SHAO Qi2*** （204 （Departmentof Thyroid and Breast Surgery，Affiliated NantongHospital 3of Nantong University，Jiangsu 226OO6; ²Department of Chemotherapy，Afiliated Hospital of Nantong University）

[Abstract]Objective：Toinvestigate thesurvival benefitsofcapecitabinemaintenance therapyinadvancd triple-negative breastcancer.Methods：Seventycasesof advanced triple-negativebreastcancerinAfiliated Hospitalof Nantong University fromJanuary2020toJanuary2O22 werecollctedanddividedintocontrolgroup（TXchemotherapyregimen）andobservation group（TXchemotherapyregimen+capecitabinemaintenance therapy）accrding todiferenttreatmentregiments.Theclinical efcacyof thetwogroupswascompared，andthelevelsofserumtumormarkers，inflammatoryesponseindicators，mmune function indicators，adversereactionsandsurvivalafter24monthsoffollow-upweredetected.Results：Theefectofobservation group was better than that of control group（ P <0.05）.After treatment， the levels of tumor markers and inflammatory factors were decreased inboth groupscompared with before treatment，andthelevels werelower inobservation group（P 0.05）.After 24 months of follow-up，the survival was 22 cases（62.86 % ） in the observation group and 12 cases（34.29 % ） in the control group，and the difference in 24- month survival rate between the two groups was statistically significant（Log-rank χ2 =6.555， P<0.05 ）.Conclusion： Capecitabine maintenance therapycannotonlyeffctivelyreduce the levelof serum tumor markersandbutalso improve inflammatory response，theimmune functionand prognosisof patientswithadvanced triple-negative breastcancer，and hasacertainsafety. [Key Words]advanced breast cancer; capecitabine; tumor markers; inflammatory response; immune function

乳腺癌作为女性常见恶性肿瘤，其临床通常表现为乳房肿块、皮肤改变、乳头回缩、溢液等症状。（剩余8421字）